الإحصائيات الأساسية
| LEI | 62QBXGPJ34PQ72Z12S66 |
| CIK | 318154 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Amgen Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 6, 2025 |
Exhibit 10.19.3 Amgen Inc. 1 Amgen Center Drive Thousand Oaks, CA 91320 USA (805) 447-1000 amgen.com May 9, 2025 BeiGene Switzerland GmbH Aeschengraben 27 4051 Basel Switzerland Attention: Managing Director BeOne Medicines USA, Inc. 55 Cambridge Parkway, Suite 700W Cambridge, Massachusetts 02142 USA Attention: General Counsel Re: Sales Force FTE Invoicing Methodology Reference is made to that cert |
|
| August 6, 2025 |
Amendment No. 9 to the Collaboration Agreement, dated May 20, 2025, by and between Amgen Inc. and Exhibit 10.22.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 9 TO THE COLLABORATION AGREEMENT This Amendment No. 9 to the Collaboration Agreement (this “Amendment”) is entered into as of the 20th day of May, 2025 (the “Amendme |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as spec |
|
| August 5, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2025 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 5, 2025 |
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Aug. 5, 2025) - Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2025. “We're delivering strong performance and reaching more patients with innovative medicines and biosimilars th |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 RETIREMENT AND SAVINGS PLAN FOR AMGEN MANUFACTURING LIMITED LL |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 AMGEN RETIREMENT AND SAVINGS PLAN (Full title of the plan) AMG |
|
| May 27, 2025 |
FORM 8-K Item 5.07. Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 Amgen Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37702 95-3540776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as spe |
|
| May 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 1, 2025 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 1, 2025 |
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS THOUSAND OAKS, Calif. (May 1, 2025) - Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. “Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐ Defin |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐ Defin |
|
| April 16, 2025 |
Notice of Exempt Solicitation Pursuant to Rule 14a-103 Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of Registrant: Amgen Inc. |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐ Defin |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☑ Defin |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 Amgen Inc. (Exact name of registrant as specified |
|
| February 14, 2025 |
Exhibit 10.3 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| February 14, 2025 |
Exhibit 10.2 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| February 14, 2025 |
Exhibit 21 AMGEN INC. The following is a list of subsidiaries of the Company as of December 31, 2024, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. SUBSIDIARY (Name under which subsidiary does business) STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Amgen (Europe) GmbH Switzerland Amgen Canada Inc. Canada Amgen Fremont I |
|
| February 14, 2025 |
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program Exhibit 10.5 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| February 14, 2025 |
EXHIBIT 4.32 DESCRIPTION OF AMGEN INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 11, 2025, Amgen Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1) our common stock, par value $0.0001 per share (the “Common Stock”); and (2) our 2.000% Senior Notes due |
|
| February 14, 2025 |
Amgen Inc. Insider Trading Policy. Amgen GLOBAL CORPORATE COMPLIANCE POLICY INSIDER TRADING Exhibit 19.1 1. Scope Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers, secondees, and temporary staff worldwide as well as non-employee directors of Amgen Inc. (“Covered Persons”). Consultants, contract workers, secondees, temporary staff, and non-employee directors are not Amgen |
|
| February 14, 2025 |
Policy Relating to Recovery of Erroneously Awarded Compensation. Exhibit 97 Amgen Policy on Recovery of Erroneously Awarded Compensation (effective as of October 2, 2023) 1. |
|
| February 14, 2025 |
Amgen Inc. Securities Transactions Blackout and Pre-Clearance Practices and Procedures. Exhibit 19.2 Amgen Inc. Securities Transactions Pre-Clearance Practices and Procedures The following practices must be observed whenever any Restricted Individual (a term which includes any member of Amgen’s Board of Directors, any officer of Amgen subject to Section 16 of the Securities Exchange Act of 1934 (the “34 Act”), any non-Section 16 officer of Amgen (“Amgen Officers”), and/or any other A |
|
| February 4, 2025 |
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Feb. 4, 2025) - Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023. “Robust growth in sales and earnings throughou |
|
| February 4, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2025 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2024 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 30, 2024 |
AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Oct. 30, 2024) - Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. “Strong growth in sales and earnings this quarter reflects the momentum we're building throughout our busines |
|
| August 23, 2024 |
NAMS / NewAmsterdam Pharma Company N.V. / AMGEN INC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares, nominal value EUR 0.12 per share (Title of Class of Securities) N62509109 (CUSIP Number) August 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| August 23, 2024 |
EX-99.1 2 d856951dex991.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the com |
|
| August 7, 2024 |
Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. Exhibit 10.7 RESTRICTED STOCK UNIT AGREEMENT (Director Equity Incentive Program) , Amgen Inc. Grantee: On this day of (the “Grant Date”), Amgen Inc., a Delaware corporation (the “Company”), pursuant to its Amgen Inc. 2009 Director Equity Incentive Program (as amended and/or restated from time to time, the “Program”) which implements the Amgen Inc. Second Amended and Restated 2009 Equity Incentive |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as spec |
|
| August 7, 2024 |
Amgen Inc. 2009 Performance Award Program. Exhibit 10.4 AMGEN INC. 2009 PERFORMANCE AWARD PROGRAM (Effective March 3, 2009) As Amended and Restated Through May 31, 2024 ARTICLE I PURPOSE The purpose of this document is to set forth the general terms and conditions applicable to the Amgen Inc. 2009 Performance Award Program (the “Program”) established by the Compensation and Management Development Committee of the Board of Directors of Amge |
|
| August 7, 2024 |
Exhibit 10.8 CASH-SETTLED RESTRICTED STOCK UNIT AGREEMENT (Director Equity Incentive Program) , Amgen Inc. Grantee: On this day of (the “Grant Date”), Amgen Inc., a Delaware corporation (the “Company”), pursuant to its Amgen Inc. 2009 Director Equity Incentive Program (as amended and/or restated from time to time, the “Program”) has granted to you, the grantee named above, an award (the “Award”) o |
|
| August 7, 2024 |
Exhibit 10.2 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| August 7, 2024 |
Amgen Inc. 2009 Director Equity Incentive Program. Exhibit 10.6 AMGEN INC. 2009 DIRECTOR EQUITY INCENTIVE PROGRAM (Effective May 31, 2024 (the “Effective Date”)) As Amended and Restated May 31, 2024 ARTICLE I PURPOSE The purpose of this document is to set forth the general terms and conditions of the Amgen Inc. 2009 Director Equity Incentive Program (the “Program”) established by the Board of Directors of Amgen Inc. (the “Company”) including, with |
|
| August 7, 2024 |
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. Exhibit 10.5 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| August 7, 2024 |
Exhibit 10.3 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| August 6, 2024 |
AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Aug. 6, 2024) - Amgen (NASDAQ:AMGN) today announced financial results for the second quarter 2024. “With a strong, balanced portfolio of in-market products and a rapidly advancing pipeline of innovative medicin |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2024 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 AMGEN RETIREMENT AND SAVINGS PLAN (Full title of the plan) AMG |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 THE RETIREMENT AND SAVINGS PLAN FOR AMGEN MANUFACTURING LIMITE |
|
| June 12, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Amgen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par val |
|
| June 12, 2024 |
As filed with the Securities and Exchange Commission on June 12, 2024 As filed with the Securities and Exchange Commission on June 12, 2024 Registration No. |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 31, 2024 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as spe |
|
| May 2, 2024 |
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS THOUSAND OAKS, Calif. (May 2, 2024) - Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024. “With many of our innovative products delivering strong growth and promising new medicines advancing through our p |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2024 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) |
|
| April 22, 2024 |
Peter H. Griffith Executive Vice President and Chief Financial Officer Amgen Inc. 1 Amgen Center Drive Thousand Oaks, CA 91320 USA (805) 447-1000 Direct Dial: XXX-XXX-XXXX E-mail: [email protected] April 19, 2024 Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Via email Re: Amgen Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-37702 |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) |
|
| February 14, 2024 |
EXHIBIT 4.33 DESCRIPTION OF AMGEN INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 9, 2024, Amgen Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1) our common stock, par value $0.0001 per share (the “Common Stock”); and (2) our 2.000% Senior Notes due 2 |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 Amgen Inc. (Exact name of registrant as specified |
|
| February 14, 2024 |
Agreement between Amgen Inc. and James Bradner, dated December 13, 2023. Exhibit 10.14 Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 805.447.1000 www.Amgen.com December 12, 2023 Dr. James (Jay) E. Bradner XXXXXXXX XXXXXXXX Dear Jay: Congratulations! You have made an excellent impression on Amgen and I am excited to present you with the attached offer package. As an organization dedicated to improving the lives of patients around the world, Amgen welcom |
|
| February 14, 2024 |
Form of Grant of Stock Option Agreement for the Amgen Inc Exhibit 10.2 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| February 14, 2024 |
Form of Restricted Stock Unit Agreement Exhibit 10.3 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| February 14, 2024 |
Exhibit 21 AMGEN INC. The following is a list of subsidiaries of the Company as of December 31, 2023, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. SUBSIDIARY (Name under which subsidiary does business) STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Amgen (Europe) GmbH Switzerland Amgen Australia Pty Ltd Australia Amgen |
|
| February 14, 2024 |
Fifth Amendment to the Amgen Inc. Supplemental Retirement Plan, effective January 1, 2024. Exhibit 10.9.5 FIFTH AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013 The Amgen Inc. Supplemental Retirement Plan, as Amended and Restated Effective October 16, 2013, and as subsequently amended (the “Plan”), is hereby amended, effective as of the dates below, as follows: 1.Effective January 1, 2024, Section 2.27 is amended by adding the f |
|
| February 14, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation. Exhibit 97 Amgen Policy on Recovery of Erroneously Awarded Compensation (effective as of October 2, 2023) 1. |
|
| February 14, 2024 |
Exhibit 10.17.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[*]”. Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 805.447.1000 www.Amgen.com November 14, 2016 Via facsimile and overnight courier UCB Cell |
|
| February 14, 2024 |
Exhibit 10.17 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[*]”. COLLABORATION AND LICENCE AGREEMENT Between AMGEN INC. and CELLTECH R&D LIMITED Re BEER BEER COLLABORATION AND LICENCE AGREEMENT I N DE X Article Descript |
|
| February 14, 2024 |
Exhibit 10.22.5 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”. Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 805.447.1000 www.Amgen.com December 1, 2023 Via Overnight Courier Service AstraZeneca C |
|
| February 14, 2024 |
Fourth Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2024 Exhibit 10.12.4 FOURTH AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013 The Amgen Nonqualified Deferred Compensation Plan, as Amended and Restated Effective October 16, 2013, and as subsequently amended (the “Plan”), is hereby amended, effective January 1, 2024, as follows: 1.Appendix A is amended by adding the following entity to th |
|
| February 14, 2024 |
Form of Performance Unit Agreement Exhibit 10.5 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| February 14, 2024 |
Amgen Inc. 2009 Director Equity Incentive Program. (As Amended and Restated on October 24, 2023.) Exhibit 10.6 AMGEN INC. 2009 DIRECTOR EQUITY INCENTIVE PROGRAM (Effective January 1, 2024 (the “Effective Date”)) As Amended and Restated October 24, 2023 ARTICLE I PURPOSE The purpose of this document is to set forth the general terms and conditions of the Amgen Inc. 2009 Director Equity Incentive Program (the “Program”) established by the Board of Directors of Amgen Inc. (the “Company”) includin |
|
| February 13, 2024 |
AMGN / Amgen Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0276-amgeninc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Amgen Inc Title of Class of Securities: Common Stock CUSIP Number: 031162100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuan |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 6, 2024 |
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Feb. 6, 2024) - Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022. “2023 was another year of performance and progres |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 12, 2023 AMGEN INC. |
|
| December 14, 2023 |
EX-99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION James Bradner, M.D., Joins as Executive Vice President, Research and Development, and Chief Scientific Officer David M. Reese, M.D., Named Executive Vice President and Chief Technology Officer THOUSAND OAKS, Calif. (Dec. 14, 2 |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2023 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as |
|
| October 31, 2023 |
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS THOUSAND OAKS, Calif. (October 31, 2023) - Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 20231. "We are excited about our pipeline progress and our operating performance in the third quarter," said Robert A |
|
| October 6, 2023 |
As filed with the Securities and Exchange Commission on October 6, 2023 S-8 As filed with the Securities and Exchange Commission on October 6, 2023 Registration No. |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| October 6, 2023 |
EX-4.5 Exhibit 4.5 HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Relationship to Prior Plans. The Plan is the successor to the 2014 Plan. As of the Effective Date, (i) no additional awards may be granted under the 2014 Plan; (ii) the Prior Plans’ Available Reserve plus any Returning Shares will become available for issuance pursuant to |
|
| October 6, 2023 |
EX-99.1 Exhibit 99.1 One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC Advances Amgen’s Mission to Serve Patients With First-in-Class Rare Disease Medicines THOUSAND OAKS, Calif. (Oct. 6, 2023) – Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Ther |
|
| October 6, 2023 |
Horizon Therapeutics Public Limited Company Amended and Restated 2014 Equity Incentive Plan EX-4.3 Exhibit 4.3 HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Relationship to Prior Plans. This Plan is intended as the successor to the Horizon Pharma, Inc. 2011 Equity Incentive Plan (the “2011 Plan”) with respect to grants to Employees. From and after 12:01 a.m. on the Effective Date, all outstanding stock awards granted under the |
|
| October 6, 2023 |
EX-4.4 Exhibit 4.4 HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN (As Amended and Restated Effective July 29, 2021) 1. PURPOSES OF THE PLAN; ASSUMPTION OF PLAN. The purposes of the Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the busine |
|
| October 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Amgen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| September 27, 2023 |
EX-3 Exhibit 3 RBNC THERAPEUTICS, INC. September 10, 2021 Amgen Inc. One Amgen Center Drive Thousand Oaks, California 91320 Attn: Re: Letter Agreement regarding the acquisition of shares of Series A-2 Preferred Stock by Amgen Inc. (“Amgen”, together with its Affiliates (as defined below), the “Investor”) of RBNC Therapeutics, Inc. (the “Company”) Ladies and Gentlemen: Reference is made to (i) that |
|
| September 27, 2023 |
EX-4 Exhibit 4 September 22, 2022 Neumora Therapeutics, Inc. 65 Grove Street Watertown, Massachusetts 02472 ATTENTION: Chief Executive Officer Re: Amendment to Letter Agreement Ladies and Gentlemen: Reference is made to that certain Letter Agreement, dated as of September 10, 2021, by and between Amgen Inc. (“Amgen”) and Neumora Therapeutics, Inc. (f/k/a RBNC Therapeutics, Inc.; the “Company”), re |
|
| September 27, 2023 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Neumora Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 640979100 (CUSIP Number) Jonathan P. Graham Executive Vice President and General Counsel and Secretary One Amgen Center Drive Thousand Oaks, CA 91320-1799 (805) |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| September 1, 2023 |
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION EX-99.1 Exhibit 99.1 One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION THOUSAND OAKS, Calif., & DUBLIN (September 1, 2023) – Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Fed |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as spec |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2023 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 3, 2023 |
Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS Positive Top-Line Results for Tarlatamab in Small Cell Lung Cancer Positive Top-Line Results for LUMAKRAS® (Sotorasib) Plus Vectibix® (Panitumumab) in Metastatic Colorectal Cancer THOUSAND OAKS, Calif. (August 3, 2023) - Amgen (NASDAQ:AMG |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 AMGEN RETIREMENT AND SAVINGS PLAN (Full title of the plan) AMG |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 THE RETIREMENT AND SAVINGS PLAN FOR AMGEN MANUFACTURING, LIMIT |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 16, 2023 |
AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS EX-99.1 Exhibit 99.1 One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS THOUSAND OAKS, Calif. (May 16, 2023) – Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission’s (FTC) complaint seeking to block the company’s propo |
|
| May 16, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 3, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐ De |
|
| April 28, 2023 |
Exhibit 10.20.2 EXECUTION VERSION CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO COLLABORATION AGREEMENT This Second Amendment to the Collaboration Agreement (“Amendment”) is entered into as of February 26, 2023 (the “Seco |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as spe |
|
| April 27, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2023 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 27, 2023 |
AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS THOUSAND OAKS, Calif. (April 27, 2023) - Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2023. "We delivered 14% volume growth driven by the breadth of our portfolio and strong demand for our products globall |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐ Definitive |
|
| April 14, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐ De |
|
| April 6, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ☐ De |
|
| April 6, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| March 9, 2023 |
EX-10.1 Exhibit 10.1 EXECUTION COPY THIRD AMENDED AND RESTATED CREDIT AGREEMENT Dated as of March 9, 2023 among Amgen Inc., The Borrowing Subsidiaries Herein Named, The Banks Herein Named, Citibank, N.A., as Administrative Agent, JPMorgan Chase Bank, N.A., as Syndication Agent, Citibank, N.A. JPMorgan Chase Bank, N.A. BofA Securities, Inc. Goldman Sachs Bank USA and Morgan Stanley Senior Funding, |
|
| March 2, 2023 |
EX-4.2 Exhibit 4.2 OFFICER’S CERTIFICATE OF AMGEN INC. Dated as of March 2, 2023 The undersigned officer of the Company certifies, pursuant to resolutions duly adopted by the Board of Directors at a meeting duly held on December 9, 2022 and by the Pricing Committee of the Board of Directors of the Company on February 13, 2023 (the “Resolutions”), and in accordance with Sections 2.1, 2.2 and 2.3 of |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| February 17, 2023 |
Exhibit 107 Calculation of Filing Fees Tables 424(b)(2) (Form Type) Amgen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forw |
|
| February 17, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-269670 Prospectus Supplement (To Prospectus Dated February 9, 2023) $2,000,000,000 5.250% Senior Notes due 2025 $1,500,000,000 5.507% Senior Notes due 2026 $3,750,000,000 5.150% Senior Notes due 2028 $2,750,000,000 5.250% Senior Notes due 2030 $4,250,000,000 5.250% Senior Notes due 2033 $2,750,000,000 5.600% Senior Notes due 2 |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 16, 2023 |
EX-1.1 Exhibit 1.1 AMGEN INC. $2,000,000,000 5.250% SENIOR NOTES DUE 2025 $1,500,000,000 5.507% SENIOR NOTES DUE 2026 $3,750,000,000 5.150% SENIOR NOTES DUE 2028 $2,750,000,000 5.250% SENIOR NOTES DUE 2030 $4,250,000,000 5.250% SENIOR NOTES DUE 2033 $2,750,000,000 5.600% SENIOR NOTES DUE 2043 $4,250,000,000 5.650% SENIOR NOTES DUE 2053 $2,750,000,000 5.750% SENIOR NOTES DUE 2063 Underwriting Agree |
|
| February 16, 2023 |
Filed Pursuant to Rule 433 Registration Statement 333-269670 February 15, 2023 Amgen Inc. |
|
| February 14, 2023 |
Subject to Completion Preliminary Prospectus Supplement, dated February 14, 2023 Table of Contents This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. |
|
| February 10, 2023 |
US4718711033 / JASPER THERAPEUTICS INC / AMGEN INC - SC 13G/A Passive Investment SC 13G/A 1 d447460dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, $0.0001 par value per share (Title of Class of Securities) 471871 103 (CUSIP Number) January 31, 2023 (Date of Event Which Requires Filing of this Stat |
|
| February 9, 2023 |
EX-FILING FEES 5 d416616dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Amgen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offeri |
|
| February 9, 2023 |
AMGN / Amgen, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0250-amgeninc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Amgen Inc. Title of Class of Securities: Common Stock CUSIP Number: 031162100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursua |
|
| February 9, 2023 |
Exhibit 4.34 DESCRIPTION OF AMGEN INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 6, 2023, Amgen Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1) our common stock, par value $0.0001 per share (the “Common Stock”); and (2) our 2.000% Senior Notes due 2 |
|
| February 9, 2023 |
Exhibit 10.5 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| February 9, 2023 |
EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. (Exact name of trustee as specified in its charter) Californ |
|
| February 9, 2023 |
Exhibit 21 AMGEN INC. The following is a list of subsidiaries of the Company as of December 31, 2022, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. SUBSIDIARY STATE OR OTHER JURISDICTION OF (Name under which subsidiary does business) INCORPORATION OR ORGANIZATION Amgen (Europe) GmbH Switzerland Amgen Canada Inc. Canada Amgen Fremont I |
|
| February 9, 2023 |
Exhibit 10.16.1 AMENDMENT NO. 1 TO THE CREDIT AGREEMENT Dated as of December 29, 2022 AMENDMENT NO. 1 TO THE CREDIT AGREEMENT (this “Amendment”) among Amgen Inc., a Delaware corporation (the “Company”), each financial institution whose name is set forth on the signature pages hereof as a Bank, Citibank, N.A. (“Citibank”), as the Administrative Agent and an Issuing Bank. PRELIMINARY STATEMENTS: (1) |
|
| February 9, 2023 |
Exhibit 10.7 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| February 9, 2023 |
As filed with the Securities and Exchange Commission on February 9, 2023 Table of Contents As filed with the Securities and Exchange Commission on February 9, 2023 Registration No. |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 Amgen Inc. (Exact name of registrant as specified |
|
| February 9, 2023 |
Fourth Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2022. Exhibit 10.11.4 FOURTH AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013 The Amgen Inc. Supplemental Retirement Plan, as Amended and Restated Effective October 16, 2013 (the “Plan”), is hereby amended, effective October 20, 2022, as follows: 1.Section 2.27 is amended by adding the following at the end thereof: If you were employed by ChemoC |
|
| February 9, 2023 |
Exhibit 10.4 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2023 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 31, 2023 |
Exhibit 99.2 Amgen Inc. Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy Beginning January 1, 2022, Amgen Inc. (the Company) no longer excludes adjustments for upfront license fees, development milestones and in-process research and development (IPR&D) expenses of pre-approval programs related to licensing, collaboration and asset acquisition transaction |
|
| January 31, 2023 |
Exhibit 10.1 AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT THIS AMENDMENT NO. 3 (this “Amendment”) to the SHARE PURCHASE AGREEMENT, dated as of October 31, 2019, as amended on December 6, 2019 and September 24, 2020 (the “Agreement”), is made and entered into as of January 30, 2023 (the “Amendment Effective Date”), by and among BeiGene, Ltd., an exempted company incorporated in the Cayman Islands (t |
|
| January 31, 2023 |
Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AMGEN ALSO PROVIDES 2023 GUIDANCE EXCLUDING ANY CONTRIBUTION FROM THE ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS THOUSAND OAKS, Calif. (January 31, 2023) - Amgen (NASDAQ:AMGN) today announced financial results for th |
|
| December 22, 2022 |
Exhibit 10.1 TERM LOAN CREDIT AGREEMENT Dated as of December 22, 2022 among Amgen Inc., The Banks Herein Named, Citibank, N.A. as Administrative Agent, Bank of America, N.A. as Syndication Agent, Goldman Sachs Bank USA and Mizuho Bank, Ltd. as Documentation Agents, and Citibank, N.A., Bank of America, N.A., Goldman Sachs Bank USA and Mizuho Bank, Ltd. as Joint Lead Arrangers and Joint Bookrunners |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 12, 2022 |
EX-2.1 Exhibit 2.1 TRANSACTION AGREEMENT dated as of December 11, 2022 among AMGEN INC. PILLARTREE LIMITED and HORIZON THERAPEUTICS PLC TABLE OF CONTENTS Page SECTION 1. INTERPRETATION 1 1.1 Definitions 1 1.2 Construction 21 SECTION 2. RULE 2.7 ANNOUNCEMENT AND SCHEME DOCUMENT 22 2.1 Rule 2.7 Announcement 22 2.2 The Scheme 22 2.3 Change in Shares 23 2.4 Company Equity Award Holder Proposal 23 SECT |
|
| December 12, 2022 |
EX-10.1 Exhibit 10.1 BRIDGE CREDIT AGREEMENT Dated as of December 12, 2022 among Amgen Inc., The Banks Herein Named, Citibank, N.A. as Administrative Agent, Bank of America, N.A. as Syndication Agent, Citibank, N.A. and Bank of America, N.A. as Lead Arrangers and Book Runners Table of Contents ARTICLE 1 DEFINITIONS AND ACCOUNTING TERMS 1.1 Defined Terms 1 1.2 Use of Defined Terms 25 1.3 Accounting |
|
| December 12, 2022 |
Appendix 3 to the Rule 2.7 Announcement, dated as of December 12, 2022 (Conditions Appendix). EX-2.2 Exhibit 2.2 APPENDIX 3 CONDITIONS OF THE ACQUISITION AND THE SCHEME The Acquisition and the Scheme will comply with the Irish Takeover Rules and, where relevant, the rules and regulations of the U.S. Exchange Act, the Irish Companies Act and the Nasdaq, and are subject to the terms and conditions set out in this Announcement and to be set out in the Scheme Document. The Acquisition and the |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2022 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 12, 2022 |
EX-99.1 Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RULES FOR IMMEDIATE RELEASE December 12, 2022 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by P |
|
| December 2, 2022 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NewAmsterdam Pharma Company N.V. (Name of Issuer) Ordinary Shares, nominal value EUR 0.12 per share (Title of Class of Securities) N62509109 (CUSIP Number) November 22, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| December 2, 2022 |
EX-99.1 Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2022 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 2, 2022 |
EX-99.1 EXHIBIT 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION December 2, 2022 Amgen Inc. (“Amgen”) Possible offer for Horizon Therapeutics plc (“Horizon”) Announcement for the purposes of Rule 2.12 of the Irish Takeover Panel Act |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as |
|
| November 4, 2022 |
EXHIBIT 10.36 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO AGREEMENT NO. 00135085 BETWEEN AMGEN USA INC. AND DAVITA INC. This Amendment No. 1 (“Amendment No. 1”) to that certain Sourcing and Supply Agreement No. 00135085 |
|
| November 3, 2022 |
Exhibit 99.2 Amgen Inc. Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy Beginning January 1, 2022, Amgen Inc. (the Company) no longer excludes adjustments for upfront license fees, development milestones and in-process research and development (IPR&D) expenses of pre-approval programs related to licensing, collaboration and asset acquisition transaction |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2022 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 3, 2022 |
AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS THOUSAND OAKS, Calif. (November 3, 2022) - Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022. Key results include: ?Total revenues decreased 1% to $6.7 billion in comparison to the third quarter of 20 |
|
| October 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 20, 2022 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| October 20, 2022 |
Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX TAVNEOS? (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) ? Amgen (NASDAQ: AMGN) today announced that it has |
|
| August 18, 2022 |
Exhibit 4.2 OFFICER?S CERTIFICATE OF AMGEN INC. Dated as of August 18, 2022 The undersigned officer of the Company certifies, pursuant to resolutions duly adopted by the Board of Directors at a meeting duly held on August 3, 2022 and by the Pricing Committee of the Board of Directors of the Company on August 12, 2022 (the ?Resolutions?), and in accordance with Sections 2.1, 2.2 and 2.3 of the Inde |
|
| August 18, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 18, 2022 |
EX-1.1 2 d280175dex11.htm EX-1.1 Exhibit 1.1 AMGEN INC. $1,250,000,000 4.050% SENIOR NOTES DUE 2029 $750,000,000 4.200% SENIOR NOTES DUE 2033 $1,000,000,000 4.875% SENIOR NOTES DUE 2053 Underwriting Agreement August 15, 2022 BofA Securities, Inc. Morgan Stanley & Co. LLC Credit Suisse Securities (USA) LLC Deutsche Bank Securities Inc. As representatives of the several Underwriters named in Schedul |
|
| August 16, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-236351 Prospectus Supplement (To Prospectus Dated February 10, 2020) $1,250,000,000 4.050% Senior Notes due 2029 $750,000,000 4.200% Senior Notes due 2033 $1,000,000,000 4.875% Senior Notes due 2053 We are offering $1,250,000,000 aggregate principal amount of 4.050% Senior Notes due 2029 (the ?2029 notes?), $750,000,000 aggreg |
|
| August 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) Amgen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa |
|
| August 15, 2022 |
FWP 1 d280177dfwp.htm FWP Filed Pursuant to Rule 433 Registration Statement 333-236351 August 15, 2022 Amgen Inc. PRICING TERM SHEET Dated August 15, 2022 $1,250,000,000 4.050% Senior Notes due 2029 (the “2029 Notes”) $750,000,000 4.200% Senior Notes due 2033 (the “2033 Notes”) $1,000,000,000 4.875% Senior Notes due 2053 (the “2053 Notes”) This term sheet relates only to the securities described b |
|
| August 15, 2022 |
Subject to Completion Preliminary Prospectus Supplement, dated August 15, 2022 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-236351 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these sec |
|
| August 5, 2022 |
EXHIBIT 10.47 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO THE COLLABORATION AGREEMENT This Amendment No. 1 to the Collaboration Agreement (this ?Amendment?) is entered into as of the 1st day of October, 2014 (the ?Amendm |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as spec |
|
| August 5, 2022 |
EXHIBIT 10.46 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Collaboration Agreement by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC Table of Contents DEFINITIONS 1 SCOPE AND GOVERNANCE 17 2.1 Purpose of the Collaboratio |
|
| August 5, 2022 |
EXHIBIT 10.41 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO COLLABORATION AGREEMENT This Amendment to the Collaboration Agreement (?Amendment?) is entered into as of April 20, 2022 (the ?Amendment Effective Date?) by and a |
|
| August 4, 2022 |
AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS THOUSAND OAKS, Calif. (August 4, 2022) - Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include: ?Total revenues increased 1% to $6.6 billion in comparison to the second quarter of 2 |
|
| August 4, 2022 |
EX-99.1 Exhibit 99.1 News Release AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease Tavneos Adds to Amgen’s Decades-Long Leadership in Inflammation and Nephrology THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 – Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), |
|
| August 4, 2022 |
Exhibit 99.2 Amgen Inc. Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy Beginning January 1, 2022, Amgen Inc. (the Company) no longer excludes adjustments for upfront license fees, development milestones and in-process research and development (IPR&D) expenses of pre-approval programs related to licensing, collaboration and asset acquisition transaction |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2022 (August 3, 2022) Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commissi |
|
| August 4, 2022 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER dated as of August 3, 2022 among CHEMOCENTRYX, INC., AMGEN INC. and CARNATION MERGER SUB, INC. TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 11 ARTICLE 2 THE MERGER Section 2.01. The Merger 12 Section 2.02. Conversion of Shares 13 Section 2.03. Surren |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2022 - Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 3, 2022 |
AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS Exhibit 99.1 One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS THOUSAND OAKS, Calif., Aug. 3, 2022 ? Amgen (NASDAQ: AMGN) today announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately. Dr. Drake will also serve as a member of the Board?s Corporate |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 AMGEN RETIREMENT AND SAVINGS PLAN (Full title of the plan) AMG |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K 11-K 1 a2021puertoricoplan11-k.htm THE RETIREMENT AND SAVINGS PLAN FOR AMGEN MANUFACTURING, LIMITED UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF |
|
| May 18, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 AMGEN INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37702 95-3540776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| April 28, 2022 |
DEFA14A 1 d142504ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMI |
|
| April 28, 2022 |
Amgen Inc. Executive Incentive Plan. EX-10.17 2 amgn-ex10172022331xq1.htm AMGEN INC. EXECUTIVE INCENTIVE PLAN Exhibit 10.17 AMGEN INC. EXECUTIVE INCENTIVE PLAN I. PURPOSE The purpose of the Amgen Inc. Executive Incentive Plan (the "Plan") is to attract and retain highly qualified individuals to Amgen Inc., and its subsidiary companies (collectively, “Amgen” or the “Company”); to obtain from each the best possible performance; to esta |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as spe |
|
| April 27, 2022 |
AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS THOUSAND OAKS, Calif. (April 27, 2022) - Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2022. Key results include: ?Total revenues increased 6% to $6.2 billion in comparison to the first quarter of 2021 |
|
| April 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2022 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| April 27, 2022 |
Exhibit 99.2 Amgen Inc. Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy Beginning January 1, 2022, Amgen Inc. (the Company) no longer excludes adjustments for upfront license fees, development milestones and in-process research and development (IPR&D) expenses of pre-approval programs related to licensing, collaboration and asset acquisition transaction |
|
| April 22, 2022 |
DEFA14A 1 d261564ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMI |
|
| April 13, 2022 |
DEFA14A 1 d343008ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMI |
|
| April 5, 2022 |
DEFA14A 1 d333563ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMI |
|
| April 5, 2022 |
DEF 14A 1 d234450ddef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMIT |
|
| February 25, 2022 |
Exhibit 10.1 Form of ASR Agreement [ ], 2022 To: Amgen Inc. 1 Amgen Center Drive Thousand Oaks, CA 91320 Attn: [ ] Telephone: [ ] Email: [ ] From: [Dealer] [] [] Attention: [] Telephone: [] Email: [] Re: Issuer Forward Repurchase Transaction (Dealer Reference Number: ) Ladies and Gentlemen: The purpose of this communication (this ?Confirmation?) is to confirm the terms and conditions of the Transa |
|
| February 25, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2022 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 22, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 22, 2022 |
Exhibit 1.1 AMGEN INC. $750,000,000 3.000% SENIOR NOTES DUE 2029 $1,000,000,000 3.350% SENIOR NOTES DUE 2032 $1,000,000,000 4.200% SENIOR NOTES DUE 2052 $1,250,000,000 4.400% SENIOR NOTES DUE 2062 Underwriting Agreement February 17, 2022 BofA Securities, Inc. Morgan Stanley & Co. LLC Citigroup Global Markets Inc. Goldman Sachs & Co. LLC As representatives of the several Underwriters named in Sched |
|
| February 22, 2022 |
Exhibit 4.2 Execution Version OFFICER?S CERTIFICATE OF AMGEN INC. Dated as of February 22, 2022 The undersigned officer of the Company certifies, pursuant to resolutions duly adopted by the Board of Directors at a meeting duly held on February 16, 2022 (the ?Resolutions?), and in accordance with Sections 2.1, 2.2 and 2.3 of the Indenture, dated as of May 22, 2014 (the ?Indenture?; capitalized term |
|
| February 18, 2022 |
EX-FILING FEES 2 d282135dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) Amgen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offer |
|
| February 18, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-236351 Prospectus Supplement (To Prospectus Dated February 10, 2020) $750,000,000 3.000% Senior Notes due 2029 $1,000,000,000 3.350% Senior Notes due 2032 $1,000,000,000 4.200% Senior Notes due 2052 $1,250,000,000 4.400% Senior Notes due 2062 We are offering $750,000,000 aggregate principal amount of 3.000% Senior Notes due 20 |
|
| February 17, 2022 |
Subject to Completion Preliminary Prospectus Supplement, dated February 17, 2022 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-236351 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these sec |
|
| February 17, 2022 |
Filed Pursuant to Rule 433 Registration Statement 333-236351 February 17, 2022 Amgen Inc. |
|
| February 16, 2022 |
EXHIBIT 4.32 DESCRIPTION OF AMGEN INC.?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 14, 2022, Amgen Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): (1) our common stock, par value $0.0001 per share (the ?Common Stock?); and (2) our 2.000% Senior Notes due |
|
| February 16, 2022 |
Third Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2022. EX-10.23 7 amgn-ex102320211231xq4.htm THIRD AMENDMENT TO NONQUALIFIED DEFERRED COMPENSATION PLAN EXHIBIT 10.23 THIRD AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013 The Amgen Nonqualified Deferred Compensation Plan, as Amended and Restated Effective October 16, 2013 (the “Plan”), is hereby amended, effective January 1, 2022, as foll |
|
| February 16, 2022 |
Third Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2021. EXHIBIT 10.15 THIRD AMENDMENT TO THE AMGEN INC. SUPPLEMENTAL RETIREMENT PLAN AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013 The Amgen Inc. Supplemental Retirement Plan, as Amended and Restated Effective October 16, 2013 (the ?Plan?), is hereby amended, effective October 20, 2021, as follows: 1.Section 2.27 is amended by adding the following at the end thereof: If you were employed by Five Prim |
|
| February 16, 2022 |
EXHIBIT 10.5 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| February 16, 2022 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| February 16, 2022 |
Exhibit 21 AMGEN INC. The following is a list of subsidiaries of the Company as of December 31, 2021, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. SUBSIDIARY STATE OR OTHER JURISDICTION OF (Name under which subsidiary does business) INCORPORATION OR ORGANIZATION Amgen (Europe) GmbH Switzerland Amgen Canada Inc. Canada Amgen Fremont I |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 Amgen Inc. (Exact name of registrant as specified |
|
| February 16, 2022 |
EXHIBIT 10.25 AIRCRAFT TIME SHARING AGREEMENT This Agreement is made and entered into as of December 3, 2021 by and between Amgen Inc. (together with its subsidiaries and affiliates, ?Lessor?), and Robert A. Bradway (?Lessee?). WITNESSETH: WHEREAS, Lessor is the operator and/or registered owner of undivided interests in aircraft bearing the Manufacturer?s Serial Number(s) and the United States Fed |
|
| February 16, 2022 |
EXHIBIT 10.4 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| February 16, 2022 |
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended EXHIBIT 10.7 Form of Award Notice [The information set forth in this Award Notice will be contained on the related pages on Merrill Lynch Benefits Website (or the website of any successor company to Merrill Lynch Bank & Trust Co., FSB). This Award Notice shall be replaced by the equivalent pages on such website. References to Award Notice in this Agreement shall then refer to the equivalent pages |
|
| February 11, 2022 |
AMGN / Amgen, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* Amgen Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 031162100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 9, 2022 |
AMGN / Amgen, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Amgen Inc. Title of Class of Securities: Common Stock CUSIP Number: 031162100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d |
|
| February 7, 2022 |
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS THOUSAND OAKS, Calif. (February 7, 2022) - Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020. Key results include: ?For the fourth quarter, |
|
| February 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2022 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 7, 2022 |
amgn22-form25 |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2022 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 31, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT No. 3 to the Exclusive License and Collaboration Agreement between Novartis Pharma AG and Amgen Inc. This Amendment No. 3 (?Amendment?) is entered into as of January 31, |
|
| January 12, 2022 |
VIGL / Vigil Neuroscience Inc / AMGEN INC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vigil Neuroscience, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92673K 108 (CUSIP Number) January 11, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as |
|
| November 3, 2021 |
Third Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2022. Exhibit 99.4 THIRD AMENDMENT TO THE AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN AS AMENDED AND RESTATED EFFECTIVE OCTOBER 16, 2013 The Amgen Nonqualified Deferred Compensation Plan, as Amended and Restated Effective October 16, 2013 (the ?Plan?), is hereby amended, effective January 1, 2022, as follows: 1. Section 3.3 (?Delayed Commencement Election?) is amended by adding the following at the en |
|
| November 3, 2021 |
As filed with the Securities and Exchange Commission on November 3, 2021 As filed with the Securities and Exchange Commission on November 3, 2021 Registration No. |
|
| November 3, 2021 |
As filed with the Securities and Exchange Commission on November 3, 2021 As filed with the Securities and Exchange Commission on November 3, 2021 Registration No. |
|
| November 3, 2021 |
Exhibit 2.7 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT AND PLAN OF MERGER dated as of July 27, 2021 by and among AMGEN INC., TUXEDO MERGER SUB, INC., TENEOBIO, INC., and FORTIS ADVISORS LLC, as the Pre-Closing Holders? Represe |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2021 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| November 2, 2021 |
AMGEN REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS EX-99.1 2 amgn-2021930xq3ex991.htm EX-99.1 Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS THOUSAND OAKS, Calif. (November 2, 2021) - Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2021. Key results include: •Total revenues increased 4% to $6.7 billi |
|
| October 1, 2021 |
AMHC / Amplitude Healthcare Acquisition Corp / AMGEN INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, $0.0001 par value per share (Title of Class of Securities) 471871 103 (CUSIP Number) September 24, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| August 9, 2021 |
Exhibit 4.2 Execution Version OFFICER?S CERTIFICATE OF AMGEN INC. Dated as of August 9, 2021 The undersigned officer of the Company certifies, pursuant to resolutions duly adopted by the Board of Directors at a meeting duly held on May 18, 2021, and by the Pricing Committee of the Board of Directors of the Company on July 29, 2021 (the ?Resolutions?), and in accordance with Sections 2.1, 2.2 and 2 |
|
| August 9, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 9, 2021 |
Exhibit 1.1 AMGEN INC. $1,250,000,000 1.650% SENIOR NOTES DUE 2028 $1,250,000,000 2.000% SENIOR NOTES DUE 2032 $1,150,000,000 2.800% SENIOR NOTES DUE 2041 $1,350,000,000 3.000% SENIOR NOTES DUE 2052 Underwriting Agreement August 5, 2021 Citigroup Global Markets Inc. Morgan Stanley & Co. LLC Barclays Capital Inc. Goldman Sachs & Co. LLC As representatives of the several Underwriters named in Schedu |
|
| August 6, 2021 |
424B2 1 d180187d424b2.htm 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-236351 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to Be Registered Amount to be Registered Proposed Maximum Offering Price per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) 1.650% Senior Notes due 2028 $1,250,000,000 99.908% $1,248,850,000 $1 |
|
| August 6, 2021 |
Filed Pursuant to Rule 433 Registration Statement 333-236351 August 5, 2021 Amgen Inc. |
|
| August 5, 2021 |
Subject to Completion Preliminary Prospectus Supplement, dated August 5, 2021 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-236351 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these sec |
|
| August 4, 2021 |
Exhibit 10.49 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMGEN INC. and KYOWA KIRIN CO., LTD. Dated June 1, 2021 LICENSE AND COLLABORATION AGREEMENT CONTENTS Page Article I. Definitions 1 Article II. Scope and Governance 27 Section 2.1 |
|
| August 4, 2021 |
Exhibit 10.39 EXECUTION VERSION CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amended and Restated Collaboration Agreement By and Between Amgen Inc. and Novartis Pharma AG Dated June 2, 2021 2017774574-009 2" = "2" "169527475" "" 169527475 |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as spec |
|
| August 3, 2021 |
AMGEN REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS THOUSAND OAKS, Calif. (August 3, 2021) - Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2021. Key results include: ?Total revenues increased 5% to $6.5 billion in comparison to the second quarter of 2 |
|
| August 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2021 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 30, 2021 |
AMGEN APPOINTS S. OMAR ISHRAK TO BOARD OF DIRECTORS Exhibit 99.1 One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN APPOINTS S. OMAR ISHRAK TO BOARD OF DIRECTORS THOUSAND OAKS, Calif. (July 29, 2021) ? Amgen (NASDAQ:AMGN) today announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately. Dr. Ishrak will also serve as a member of the Board?s Corporate Responsib |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2021 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 27, 2021 |
Exhibit 99.1 News Release AMGEN TO ACQUIRE PRIVATELY HELD TENEOBIO FOR $900 MILLION IN CASH WITH FUTURE CONTINGENT MILESTONE PAYMENTS Acquisition Complements Amgen?s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer THOUSAND OAKS, Calif. and NEWA |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K 11-K 1 a2020puertoricoplan11-k.htm THE RETIREMENT AND SAVINGS PLAN FOR AMGEN MANUFACTURING, LIMITED UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 11-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 AMGEN RETIREMENT AND SAVINGS PLAN (Full title of the plan) AMG |
|
| June 1, 2021 |
Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease Areas KHK4083 Depletes OX40-E |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 19, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 AMGEN INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37702 95-3540776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the registrant ? Filed by a party other than the registrant Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) ? Definitive |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as spe |
|
| April 28, 2021 |
DEFA14A 1 d132478ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the registrant ☐ Filed by a party other than the registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMI |
|
| April 27, 2021 |
AMGEN REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS THOUSAND OAKS, Calif. (April 27, 2021) - Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2021. Key results include: ?Total revenues decreased 4% to $5.9 billion in comparison to the first quarter of 2020 |
|
| April 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2021 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 001-37702 95-3540776 (State or other jurisdiction of incorporation) (Commission File Number) ( |
